Biodegradable sirolimus-eluting stents show more durable long-term effect

The long-term benefits of biodegradable polymer sirolimus-eluting stents after complete degradation compared to durable polymer everolimus-eluting stents have been identified. The study involved patients from Switzerland.

Scientists from the universities of Geneva and Bern, as well as several specialized Swiss centers, assessed the failure rates of two types of stents five years after stenting in patients in Switzerland for acute ST-segment elevation myocardial infarction. The results of the study were published in The Lancet.

Three years of data from 1,300 patients were analyzed. Participants were divided into two groups: biodegradable polymer sirolimus-eluting stents (649 patients) and durable polymer everolimus-eluting stents (651 patients). At five years, rates of target lesion failure were compared, including rates of cardiovascular mortality, target-vessel recurrent myocardial infarction, or clinically indicated target-lesion revascularization.

Five years after stenting, the stent failure rate was 8% in the sirolimus-eluting biodegradable polymer stent group and 11% in the second group. The main difference was due to the lower rate of target lesion revascularization caused by ischemia.

Thus, the risk of long-term stent failure five years after stenting was 30% higher with durable polymer everolimus-eluting stents compared with biodegradable sirolimus-eluting stents.

Source link